Elicio Therapeutics Inc. (ELTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $42.46M
Last updated: Nov 17, 2026 at 4:29 PM ET
Elicio Therapeutics Inc. (ELTX) Statistics
Elicio Therapeutics (ELTX) has a market cap of $42.46M and an enterprise value of $21.20M. Its share count is up 57.51% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 50.08% below the market cap, as cash exceeds debt.
| Market Cap | $42.46M |
|---|---|
| Enterprise Value | $21.20M |
| Latest price (Nov 17, 2026) | $1.43 |
Key Dates
The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 83.95% over 52 weeks and trades 19.21% below its 50-day average.
| Beta (1Y) | 0.32 |
|---|---|
| 52-Week Change | -83.95% |
| 1-Month Change | -7.74% |
| 3-Month Change | -54.31% |
| 6-Month Change | -84.41% |
| 5-Year Change | -95.97% |
| Total Return (1Y) | -83.95% |
| Total Return (3Y CAGR) | -37.68% |
| Total Return (5Y CAGR) | -49.01% |
| Return vs SPY (1Y) | -94.87% |
| Max Drawdown (1Y) | -90.57% |
| Max Drawdown (3Y) | -90.57% |
| Sharpe Ratio (1Y) | -1.02 |
| Correlation with SPY (1Y) | 0.02 |
| 50-Day Average | $1.77 |
| 200-Day Average | $6.39 |
| 52-Week Range | $1.25 to $16.00 |
| RSI (14 Days) | 37.4 |
| Average Volume (20 Days) | 335.97K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.43x current liabilities, and total debt is 0.51x shareholder equity.
| Current Ratio | 3.43x |
|---|---|
| Quick Ratio | 3.43x |
| Debt / Equity | 0.51x |
| Interest Coverage | -22.24x |
Returns and Efficiency
Return on invested capital is -96.64% and return on equity is -189.58% over the last 12 months.
| Return on Equity (ROE) | -189.58% |
|---|---|
| Return on Assets (ROA) | -90.25% |
| Return on Invested Capital (ROIC) | -96.64% |
| Return on Capital Employed (ROCE) | -117.46% |
Scores
ELTX has a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 4 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$286.00K |
| Operating Income | -$38.33M |
| Pretax Income | -$35.68M |
| Net Income | -$35.74M |
| EBITDA | -$33.29M |
| EBIT | -$34.85M |
| Reported EPS (TTM) | -$1.87 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 47.60% of the $39.60M in total assets.
| Cash and Equivalents | $30.90M |
|---|---|
| Total Debt | $9.63M |
| Net Cash | $21.27M |
| Net Cash Per Share | $0.81 |
| Working Capital | $24.11M |
| Shareholder Equity | $18.85M |
| Book Value Per Share | $0.72 |
| Total Assets | $39.60M |
| Total Liabilities | $20.75M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$36.97M |
|---|---|
| FCF Per Share | -$1.37 |
| Depreciation and Amortization | $1.55M |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -69.98% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -69.98% |
Dividends and Yields
ELTX does not pay a dividend.
| Buyback Yield | -125.18% |
|---|---|
| Shareholder Yield | -125.18% |
Stock Splits
The last split was a 1-for-10 reverse split on Jun 2, 2023.
| Last Split Date | Jun 2, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Peer Position
Against 5 similar companies, ELTX has the 3rd highest ROIC.
ROICPeer median -109.01%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -32.90%
| ROIC | -96.64% vs -109.01% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -100.00% vs -32.90% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About ELTX
What is ELTX's market cap?
Elicio Therapeutics has a market cap of $42.46M. Its enterprise value, which adds debt and subtracts cash, is $21.20M.
How many shares of ELTX are outstanding?
Elicio Therapeutics has 26.29M shares outstanding. The count is up 57.51% from a year earlier.
Does ELTX pay a dividend?
No. Elicio Therapeutics does not pay a dividend.
How much debt does ELTX have?
Elicio Therapeutics has $9.63M of total debt and $30.90M of cash and equivalents, a net cash position of $21.27M.
ELTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors